The triple-angiokinase inhibitor nintedanib, which effectively blocks fibroblast growth factor receptor 1–3 (FGFR), has been investigated for lung diseases and could be considered a treatment option for BM35 [43]. Here, FGFR1 is linked to lung disorder.